Alina Carmen Porojnicu
Overview
Explore the profile of Alina Carmen Porojnicu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
520
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Svalastoga M, Larsen T, Brekke J, Enden T, Froen H, Garresori H, et al.
Front Oncol
. 2025 Feb;
15:1520725.
PMID: 39931081
Introduction: It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients. Methods: A analysis of a single-arm interventional clinical trial on apixaban treatment...
2.
Fjermeros K, Ghannoum S, Geisler S, Bhargava S, Tahiri A, Klajic J, et al.
Future Oncol
. 2024 Jul;
20(32):2457-2466.
PMID: 39073142
Chemotherapy is used as neoadjuvant therapy for all subgroups of breast cancer, including ER-positive, and HER2-negative cases. However, studies have suggested that using aromatase inhibitors combined with CDK4/6-inhibitors might be...
3.
Skjerven H, Myklebust E, Korvald C, Stubberud K, Hovda T, Porojnicu A, et al.
Eur J Surg Oncol
. 2024 Jan;
50(2):107938.
PMID: 38199004
Background: Few studies evaluate oncological safety in complex oncoplastic breast-conserving surgery(C-OBCS) for DCIS. It still needs to be defined whether it is equivalent to standard breast conservation(S-BCS) or an alternative...
4.
Larsen T, Svalastoga M, Brekke J, Enden T, Froen H, Garresori H, et al.
Thromb Res
. 2023 Jun;
228:128-133.
PMID: 37327527
Introduction: In a recent interventional study of cancer patients with newly diagnosed venous thrombosis (VT), we found a high risk of arterial thrombotic events (AT) during treatment with therapeutic doses...
5.
Skjerven H, Myklebust E, Korvald C, Porojnicu A, Kaaresen R, Hofvind S, et al.
Eur J Surg Oncol
. 2022 Dec;
49(3):575-582.
PMID: 36509629
Background: For Ductal Carcinoma in Situ (DCIS), recurrence is shown to be higher after skin-sparing (SSM) versus simple (SM) mastectomy. This study aimed to compare the two groups recurrence rates,...
6.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost
. 2022 Jul;
20(8):1937-1939.
PMID: 35859282
No abstract available.
7.
Larsen T, Garresori H, Brekke J, Enden T, Froen H, Jacobsen E, et al.
J Thromb Haemost
. 2022 Feb;
20(5):1166-1181.
PMID: 35114046
Background: There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban...
8.
Hannevik T, Brekke J, Enden T, Froen H, Garresori H, Jacobsen E, et al.
Thromb Res
. 2020 Sep;
196:238-244.
PMID: 32919178
Introduction: The direct oral anti-coagulants (DOAC) edoxaban and rivaroxaban are suggested treatment alternatives for cancer-associated venous thromboembolism (VTE) together with low molecular-weight heparins. New studies indicate that the DOAC apixaban...
9.
Thorsteinsdottir T, Loitegard T, Reims H, Porojnicu A
Case Rep Oncol
. 2020 Aug;
13(2):659-663.
PMID: 32774252
The use of immune checkpoint inhibitors has dramatically improved the chance of surviving malignant melanomas; however, the effect comes at the cost of toxicities that are difficult to predict. Immune-mediated...
10.
Juzeniene A, Porojnicu A, Baturaite Z, Lagunova Z, Aksnes L, Bruland O, et al.
Anticancer Res
. 2015 Feb;
35(2):1171-80.
PMID: 25667508
Background: Calcitriol [1,25(OH)2D] is hypothesized to lower the risk of cancer via binding to the vitamin D receptor (VDR). VDRs are also found in benign and malignant cells of mesenchymal...